RVNC—The RT002 BLA submission is awaiting completion of SAKURA-3, the open-label safety study that includes repeat injections for glabellar lines and follows patients for 12 months:
If the FDA permits RVNC to submit the BLA based on interim SAKURA-3 data (to be updated with the final data during the BLA review), then RT002 could be on the market in late 2019 rather than 2020.
Market Data 
Markets 
AI
